Drug Trial Radar · NCT05584631
IVIG vs SCIG in CIDP
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 11, 2022
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Rutgers, The State University of New JerseyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Conditions
- CIDP
- Immunoglobulin Deficiency
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Intravenous immune globulin GDrug
Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
Subcutaneous immune globulin GDrug
Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of drug half-lifeTime frame: Through study completion, an average of 4 weeks
- Assessment of immune globulin G serum concentration after intravenous immune globulin G administrationTime frame: Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
- Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administrationTime frame: Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rutgers, The State University of New Jersey Clinical Research Center
New Brunswick, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.